An investigation of the efficacy of clarithromycin in treatment of mycoplasma infection in adults
Shigeru Kohnoa Jun-ichi Kadotab Hiroshi Tanakac Naoyuki Miyashitad Hiroto Matsusee Koichi Izumikawaf Kazunobu Ouchig
aDepartment of Internal Medicine, Nagasaki University School of Medicine
bDepartment of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine
cNPO Sapporo Cough Asthma and Allergy Center
dDepartment of Internal Medicine 1, Kawasaki Medical School
eDivision of Respirology, Department of Internal Medicine, Toho University Ohashi Medical Center
fDepartment of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences
gDepartment of Pediatrics, Kawasaki Medical School
We conducted a specified drug-use investigation in 2014 for mycoplasma infection in adults to review the current outcome of treatment with clarithromycin, while isolation of macrolide-resistant mycoplasma was being reported. Of 31 patients with confirmed mycoplasma infection, clarithromycin treatment was successful in 5 and mild improvement in 26 in terms of infection outcome; clinical efficacy was confirmed in all patients. Clarithromycin treatment was also effective in a patient who was infected with mycoplasma carrying macrolide-resistant genes and had all the characteristic symptoms, including coughing, that were alleviated by the end of the treatment period. The present investigation demonstrated favorable results of clarithromycin treatment for the treatment of mycoplasma infection in adults.
Mycoplasma pneumoniae Clarithromycin Bronchitis Infectious cough Clinical study
Received 1 Sep 2015 / Accepted 20 Nov 2015
AJRS, 5(2): 64-70, 2016